1. Home
  2. AEZS

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Pharmaceuticals and Biotechnology

Nasdaq

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

Founded: N/A Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 10.2M IPO Year: 1996
Target Price: $60.00 AVG Volume (30 days): 6.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -13.64 EPS Growth: N/A
52 Week Low/High: $5.44 - $12.80 Next Earning Date: 05-14-2024
Revenue: $4,498,000 Revenue Growth: -20.25%
Revenue Growth (this year): -2.49% Revenue Growth (next year): N/A

Share on Social Networks: